Concepedia

Wei Meng

WM

Statistics

Publications

31

Citations

2.5K

H-Index

19

Active since

1989

Affiliations

Bristol-Myers Squibb (United States)(Current)

Bristol-Myers Squibb (Germany)

Hubei University of Science and Technology

Affiliated Hospital of Shandong University of Traditional Chinese Medicine

Bristol-Myers Squibb (Sweden)

Wei Meng is an author at Bristol-Myers Squibb (United States) specializing in pharmacology, drug discovery, and medicinal chemistry.

ORCID

Publications per year

1989–2024

31

Publications

31

Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

Wei Meng, Bruce A. Ellsworth, Alexandra A. Nirschl et al. · Journal of Medicinal Chemistry · 2008 · 628 citations · Full text

, , +17

Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats

Song‐Ping Han, Deborah Hagan, Joseph R. Taylor et al. · Diabetes · 2008 · 418 citations · Full text

, , +16

The Pinene Path to Taxanes. 6. A Concise Stereocontrolled Synthesis of Taxol

Paul A. Wender, Neil F. Badham, Simon P. Conway et al. · Journal of the American Chemical Society · 1997 · 247 citations

, , +5

Depletion of neutrophil extracellular traps in vivo results in hypersusceptibility to polymicrobial sepsis in mice

Wei Meng, Adnana Paunel‐Görgülü, Sascha Flohé et al. · Critical Care · 2012 · 200 citations · Full text

, , +13

The Pinene Path to Taxanes. 5. Stereocontrolled Synthesis of a Versatile Taxane Precursor

Paul A. Wender, Neil F. Badham, Simon P. Conway et al. · Journal of the American Chemical Society · 1997 · 172 citations

, , +5

1–5 of 31